MatVPC: A user-friendly MATLAB-based tool for the simulation and evaluation of systems pharmacology models

CPT: Pharmacometrics and Systems Pharmacology

Volumn 4, Issue 9, 2015, Pages 547-557

  Biliouris, K ^a   Lavielle, M ^b   Trame, M N ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b INRIA SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COMPUTER PROGRAM; MATVPC; MONTE CARLO METHOD; PREDICTIVE VALUE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SENSITIVITY ANALYSIS; SIMULATION;

EID: 84942553115     PISSN: None     EISSN: 21638306     Source Type: Journal    
DOI: 10.1002/psp4.12011     Document Type: Article

References (46)

1. Karlsson, M., &, Holford, N., A tutorial on visual predictive checks, PAGE meeting, Marseille, France, 2008.
2. Brendel, K., et al., Are population pharmacokinetic and/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004. Clin. Pharmacokinet. 46, 221-234 (2007).
3. Byon, W., et al., Establishing best practices and guidance in population modeling: an experience with an internal population pharmacokinetic analysis guidance. CPT Pharmacometrics Syst. Pharmacol. 2, e51 (2013).
4. Keizer, R.J., Karlsson, M.O., &, Hooker, A., Modeling and simulation workbench for NONMEM: tutorial on Pirana, PsN, and Xpose. CPT Pharmacometrics Syst. Pharmacol. 2, e50 (2013).
5. Comets, E., Brendel, K., &, Mentré, F., Model evaluation in nonlinear mixed effect models, with applications to pharmacokinetics. J. Soc. Stat. Paris 151, 106-128 (2010).
6. Holford N., The visual predictive check-superiority to standard diagnostic (Rorschach) plots. PAGE Abstracts Abstr 738, p 14 (2005).
7. European Medicines Agency. Guideline on reporting the results of population pharmacokinetic analyses, London, 21 June 2007. < http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500003067.pdf >. Accessed March 2015.
8. Bergstrand, M., Hooker, A.C., Wallin, J.E., &, Karlsson, M.O., Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 13, 143-151 (2011).
9. Lavielle, M., &, Bleakley, K., Automatic data binning for improved visual diagnosis of pharmacometric models. J. Pharmacokinet. Pharmacodyn. 38, 861-871 (2011).
10. Wang, D.D., &, Zhang, S., Standardized visual predictive check versus visual predictive check for model evaluation. J. Clin. Pharmacol. 52, 39-54 (2012).
11. Post, T.M., Freijer, J.I., Ploeger, B.A., &, Danhof, M., Extensions to the visual predictive check to facilitate model performance evaluation. J. Pharmacokinet. Pharmacodyn. 35, 185-202 (2008).
12. Monolix Lixoft., < http://www.lixoft.eu/products/monolix >.
13. Jonsson, E.N., &, Karlsson, M.O., Xpose-an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput. Methods Programs Biomed. 58, 51-64 (1999).
14. Lindbom, L., Ribbing, J., &, Jonsson, E.N., Perl-speaks-NONMEM (PsN)-a Perl module for NONMEM related programming. Comput. Methods Programs Biomed. 75, 85-94 (2004).
15. The MathWorks. SimBiology. < http://www.mathworks.com/products/simbiology/ >.
16. Wojciechowski, J., Hopkins, A.M., &, Upton, R.N., Interactive pharmacometric applications using R and the shiny package. CPT Pharmacometrics Syst. Pharmacol. 4, 146-159 (2015).
17. Guiastrennec, B., Wollenberg, L., Forrest, A., &, Ait-Oudhia, S., AMGET, an R-based postprocessing tool for ADAPT 5. CPT Pharmacometrics Syst. Pharmacol. 2, e61 (2013).
18. Bauer, R.J., NONMEM users guide: introduction to NONMEM 7.2.0 (ICON Development Solutions, Ellicott City, MD, 2011).
19. Bai, J.P., Fontana, R.J., Price, N.D., &, Sangar, V., Systems pharmacology modeling: an approach to improving drug safety. Biopharm. Drug Dispos. 35, 1-14 (2014).
20. Cucurull-Sanchez, L., Spink, K.G., &, Moschos, S.A., Relevance of systems pharmacology in drug discovery. Drug Discov. Today 17, 665-670 (2012).
21. Iyengar, R., Zhao, S., Chung, S.W., Mager, D.E., &, Gallo, J.M., Merging systems biology with pharmacodynamics. Sci. Transl. Med. 4, 126ps7 (2012).
22. Sorger, P.K., et al., Quantitative and systems pharmacology in the post-genomic era: new approaches to discovering drugs and understanding therapeutic mechanisms (ed., Ward, R., ed) 1-48. An NIH white paper by the QSP Workshop Group (NIH, Bethesda, MD, 2011).
23. Visser, S.A., de Alwis, D.P., Kerbusch, T., Stone, J.A., &, Allerheiligen, S.R., Implementation of quantitative and systems pharmacology in large pharma. CPT Pharmacometrics Syst. Pharmacol. 3, e142 (2014).
24. Lei, T.A., &, Bertz, R., Quantitative systems pharmacology can reduce attrition and improve productivity in pharmaceutical research and development. Front. Pharmacol. 5, 247 (2014).
25. Mavroudis, P.D., Corbett, S.A., Calvano, S.E., &, Androulakis, I.P., Circadian characteristics of permissive and suppressive effects of cortisol and their role in homeostasis and the acute inflammatory response. Math. Biosci. 260, 54-64 (2015).
26. van der Graaf, P.H., &, Benson, N., Systems pharmacology: bridging systems biology and pharmacokinetics-pharmacodynamics (PKPD) in drug discovery and development. Pharm. Res. 28, 1460-1464 (2011).
27. Boran, A.D., &, Iyengar, R., Systems approaches to polypharmacology and drug discovery. Curr. Opin. Drug Discov. Devel. 13, 297-309 (2010).
28. Ballesta, A., Zhou, Q., Zhang, X., Lv H., &, Gallo, J.M., Multiscale design of cell-type-specific pharmacokinetic/pharmacodynamic models for personalized medicine: application to temozolomide in brain tumors. CPT Pharmacometrics Syst. Pharmacol. 3, e112 (2014).
29. Ait-Oudhia, S., Straubinger, R.M., &, Mager, D.E., Systems pharmacological analysis of paclitaxel-mediated tumor priming that enhances nanocarrier deposition and efficacy. J. Pharmacol. Exp. Ther. 344, 103-112 (2013).
30. Hendrix, A.O., Hughes, C.L., &, Selgrade, J.F., Modeling endocrine control of the pituitary-ovarian axis: androgenic influence and chaotic dynamics. Bull. Math. Biol. 76, 136-156 (2014).
31. Madrasi, K., Burns, R.N., Hendrix, C.W., Fossler, M.J., &, Chaturvedula, A., Linking the population pharmacokinetics of tenofovir and its metabolites with its cellular uptake and metabolism. CPT Pharmacometrics Syst. Pharmacol. 3, e147 (2014).
32. Wajima, T., Isbister, G.K., &, Duffull, S.B., A comprehensive model for the humoral coagulation network in humans. Clin. Pharmacol. Ther. 86, 290-298 (2009).
33. Gadkar, K., Budha, N., Baruch, A., Davis, J.D., Fielder, P., &, Ramanujan, S., A mechanistic systems pharmacology model for prediction of LDL cholesterol lowering by PCSK9 antagonism in human dyslipidemic populations. CPT Pharmacometrics Syst. Pharmacol. 3, e149 (2014).
34. Benson, N., et al., Systems pharmacology of the nerve growth factor pathway: use of a systems biology model for the identification of key drug targets using sensitivity analysis and the integration of physiology and pharmacology. Interface Focus 3, 20120071 (2013).
35. Toni, T., Dua, P., &, van der Graaf, P.H., Systems pharmacology of the NGF signaling through p75 and TrkA receptors. CPT Pharmacometrics Syst. Pharmacol. 3, e150 (2014).
36. Pichardo-Almarza, C., Metcalf, L., Finkelstein, A., &, Diaz-Zuccarini, V., Using a systems pharmacology approach to study the effect of statins on the early stage of atherosclerosis in humans. CPT Pharmacometrics Syst. Pharmacol. 4, 41-50 (2014).
37. Gieschke, R., &, Serafin, D., Development of innovative drugs via modeling with MATLAB (Springer, New York, NY, 2013).
38. Gulati, A., Isbister, G.K., &, Duffull, S.B., Scale reduction of a systems coagulation model with an application to modeling pharmacokinetic-pharmacodynamic data. CPT Pharmacometrics Syst. Pharmacol. 3, e90 (2014).
39. Peterson, M.C., &, Riggs, M.M., FDA advisory meeting clinical pharmacology review utilizes a quantitative systems pharmacology (QSP) model: a watershed moment? CPT Pharmacometrics Syst. Pharmacol. 4, 189-192 (2015).
40. Lavielle, M., Mixed effects models for the population approach: models, tasks, methods and tools (Chapman and Hall/CRC Biostatistics Series, 2014).
41. Combes, F.P., Retout, S., Frey, N., &, Mentré, F., Prediction of shrinkage of individual parameters using the Bayesian information matrix in non-linear mixed effect models with evaluation in pharmacokinetics. Pharm. Res. 30, 2355-2367 (2013).
42. Van Wart, S., Tsai, M., Chan, J., &, Cirincione, B.B., Modeling the time-course of body weight for subjects given placebo in an obesity trial. ACOP meeting. San Diego, CA, October 7-10, 2012.
43. Vlasakakis, G., et al., White paper: landscape on technical and conceptual requirements and competence framework in drug/disease modeling and simulation. CPT Pharmacometrics Syst. Pharmacol. 2, e40 (2013).
44. Schmidt, H., &, Jirstrand, M., Systems biology toolbox for MATLAB: a computational platform for research in systems biology. Bioinformatics 22, 514-515 (2006).
45. Zhang, X.-Y., Trame, M.N., Lesko, L.J., &, Schmidt, S., Sobol sensitivity analysis: a tool to guide the development and evaluation of systems pharmacology models. CPT Pharmacometrics Syst. Pharmacol. 4, 69-79 (2015).
46. Dokoumetzidis, A., &, Aarons, L., Proper lumping in systems biology models. IET Syst. Biol. 3, 40-51 (2009).